VolitionRx Announces First Published Data in Anticancer Research Journal

The Preliminary Data, Which Demonstrated High Detection Rates for Colorectal Cancer, Was the First to Be Publicly Shared by the Company Last Year

NAMUR, BELGIUM -- (Marketwired) -- 04/30/14 -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces that preliminary data from University Hospital Bonn, Germany, has been published online in the leading peer-reviewed journal, Anticancer Research. The data, first presented at CNAPS (Circulating Nucleic Acids in Plasma and Serum) congress last year, shows VolitionRx's single proprietary NuQ®-5mc assay detects 75% of colorectal cancers with 70% specificity. Since then, VolitionRx has achieved even better detection rates by combining its assays. The full article, "Novel Serum Nucleosomics Biomarkers for the Detection of Colorectal Cancer" is available on VolitionRx's website at http://volitionrx.com/technologies-abstracts-papers-posters.html, or at Anticancer Research's website at http://ar.iiarjournals.org/content/34/5/2357.abstract?etoc.

The independent trial at University Hospital Bonn was coordinated by Dr. Stefan Holdenrieder at the Institute of Clinical Chemistry and Clinical Pharmacology. Using VolitionRx's NuQ® assay, his team tested 90 patient samples and found significantly lower levels of nucleosomes containing methylated DNA in the blood of patients with colorectal cancer compared to healthy samples, and later validated the results in a second set of 113 people.

Last year, VolitionRx proved that it could further improve detection rates by searching for more than one nucleosome biomarker and effectively creating a 'panel' test. Using samples from CHU Dinant Godinne/UCL Namur Hospital in Belgium, the team detected 85% of colorectal cancer with 85% specificity when combining two NuQ assays.

"It is encouraging to see data supporting the use of our blood tests for the detection of colorectal cancer being published for the very first time; it is a pivotal moment for us. Dr. Holdenrieder's study was the first to acknowledge the potential of our NuQ tests," said Jake Micallef, Chief Scientific Officer of VolitionRx. "It's promising that similar results have been found independently from our own trials as we look to bring the test to market."

Dr. Holdenrieder comments, "We are very excited to have our study published in such a prestigious journal. Since this study, we have seen more and more data confirming our findings and I am eager to ensure that this bank of research continues to grow so that patients can gain access to this rapid diagnostic tool as soon as possible. As such, I recently agreed to lead a performance evaluation study for VolitionRx's CE mark application process."

Other clinical trials assessing the effectiveness of VolitionRx's assays include:

A 4,800 patient retrospective study and an 11,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark
A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany
A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream -- an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

Safe Harbor Statement

Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

Media Contacts

Charlotte Reynolds
VolitionRx
Telephone: +44 (0) 795 217 7498
Email: Charlotte.Reynolds@volitionrx.com

Jon Falcone
Racepoint Global
Phone: +44 (0) 208 811 2121
Email: Jon.Falcone@racepointglobal.com

Investor Contacts
Kirin M. Smith
Proactive Capital
E: mksmith@proactivecapital.com
T: +1 646 863 6519

Source: VolitionRx Ltd.

Released April 30, 2014